A phase 1/2, open-label, parallel group study to evaluate the preliminary efficacy and usability DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal RinGSM) over 12 weeks in healthy postmenopausal women.

Table 1 demonstrates that when the self-reported subjective severity scores (among all participants) of all four GSM symptoms were compared as continuous variables between baseline and end of treatment, there was significant improvement in vaginal dryness and dyspareunia in the IVR1 dosing group ( P values <0.01), with a nonsignificant trend in improvement ( P = 0.06) for the IVR2 dosing group.

also in 5,406 other papers